China's ophthalmic medical demand shows a continuous growth trend, the market size or more than 100 billion yuan

【Pharmaceutical Network Market Analysis】 The ophthalmic drug market has grown significantly
.

Data show that in 2021, the overall ophthalmic drug market in China will be close to 26 billion yuan
.

It is estimated that by 2030, with the continuous expansion of the scale of the ophthalmic disease population and the increase in drug penetration, the domestic ophthalmic drug market will exceed 100 billion yuan
.

In addition, judging from the 2022 semi-annual report released by pharmaceutical companies recently, the performance of some ophthalmic companies has maintained steady growth
.

For example, according to the 2022 semi-annual report released by Xingqi Eye Medicine, in the first half of this year, the company's operating income increased by 29.
89% year-on-year to 601 million yuan; the net profit attributable to the shareholders of the listed company increased by 50.
53% year-on-year to 121 million yuan
.

According to the 2022 semi-annual report of Aier Ophthalmology, in the first half of the year, Aier Ophthalmology achieved an increase of 10.
34% year-on-year to 8.
107 billion yuan; the net profit attributable to the mother increased by 15.
73% year-on-year to 1.
291 billion yuan; and the non-net profit increased by 12.
65% year-on-year to 1.
382 billion yuan
.

For the reasons for the growth in performance, Xingqi Eye Medicine is attributed to advanced production management concepts, increased investment in research and development and active market expansion activities
.

It is worth noting that Shenyang Xingqi Eye Hospital Co.
, Ltd.
, a wholly-owned subsidiary of Xingqi Eye Medicine, had a revenue of 219 million yuan and a net profit of 37.
568 million yuan in the first half of
the year.

That is to say, xingqi eye hospital alone has contributed more than 1/3 of the revenue
to xingqi eye medicine.

It is understood that in the first half of the year, Xingqi Eye Medicine continued to provide cyclosporine eye drops (II.
), calf blood deproteinization extract eye drops, diclofenac sodium eye drops, gatifloxacin eye gel, calf blood deproteinization extract eye gel, compound electrolyte flushing liquid and other products, and continued to introduce automatic online leak detection equipment, automatic online appearance testing equipment, automatic packing equipment and other new production equipment and facilities, further realizing the modernization and automation of production equipment, improving production efficiency and expanding production capacity
。
The new production equipment replaces some manual operations, improves labor productivity, reduces the risk of human error, and ensures product quality
.

Aier Ophthalmology explained that the main reasons for the growth of the company's operating performance include the enhancement of residents' awareness of eye health, the steady upgrading of medical consumption, the promotion and implementation of national policies, the continuous improvement of the company's brand influence, and the continuous expansion of the scale of operation and talent
.

Aier Ophthalmology said in the report that the company has formed its own brand advantages in medical network, professional services, technical personnel, academic research, management mechanism, etc.
, and its core competitiveness has been further improved, as of June 30, 2022, the company has 187 hospitals and 132 outpatient departments
.

Overseas, 115 ophthalmic centers and clinics have been deployed, gradually forming a global medical service network
.

The ophthalmology market has attracted the attention
of the capital market because of its huge potential.

Some insiders said that from the perspective of the general environment, the aging of the global population and the popularity of electronic products have made the incidence of eye diseases rise
year after year.

On the other hand, the private medical institutions of ophthalmology in China are booming, and the rate of disease diagnosis has been significantly improved
.

In addition, some enterprises also said that in recent years, the demand for eye medical services in China has shown a sustained growth trend, mainly because: 1, with the aging of China's population structure, age-related eye disease patients continue to increase; 2.
The eye health of adolescents is becoming increasingly severe, especially the incidence of myopia is much higher than the world average; 3.
The epidemic has changed people's lifestyles, and the trend of online classes, online offices, online entertainment, and online social networking has intensified the intensity of use of the eyes, which has a greater impact on visual health and brought more demand for
eye medical services.

At the same time, with the increasing income level of people and the continuous improvement of China's medical security system, the potential demand for ophthalmic medical care will continue to be transformed into a realistic and effective demand
.

Under the combined effect of increasing demand and consumption upgrading, the market capacity of ophthalmology diagnosis and treatment has been expanding
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.